In Primary Breast Cancer, Letrozole and Cyclophosphamide Plus Sorafenib Show Activity
the Cancer Therapy Advisor take:
According to a new small study published in the British Journal of Cancer, researchers have found that the combination of letrozole, metronomic cyclophosphamide, and sorafenib shows activity and is well tolerated for the treatment of patients with primary breast cancer.
For the study, researchers enrolled 13 postmenopausal patients with estrogen receptor-positive, T2-4, N0-1 primary breast cancer. All patients received the three-drug regimen for 6 months.
Results showed that adequate plasma concentrations of sorafenib were achieved when participants received all three drugs at the same time, but average plasma concentrations of cyclophosphamide were decreased after receiving the three drugs versus when receiving letrozole and cyclophosphamide only.
The most frequent serious adverse events were diarrhea, hand-foot skin reaction, and skin rash. Of the 13 patients, six achieved a clinical complete response per RECIST Criteria, and all patients experienced a significant decrease in tumor size (P=0.005). In addition, at 30 days, 8 of 10 evaluable patients demonstrated a response and 11 of 13 evaluable patients demonstrated a response at the time of definitive surgery.
There was also a significant reduction in certain biomarkers, such as Ki67, CD31, and VEGF-A, following treatment with letrozole, cyclophosphamide, and sorafenib.
Combination of letrozole, metronomic cyclophosphamide, and sorafenib shows activity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer